More News! 19 Nov 2018 Anti-Inflammatory Treatments Get €40M Boost in Series B …and Parkinson’s disease. “We are extremely excited about this opportunity, which is such a large funding round in a European company,” Marco Boorsma, General Partner at Forbion, the lead investor… November 19, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 13 May 2025 Nine biotech companies in Montreal to keep an eye on in 2025 …plays a crucial role in regulating appetite and energy balance – followed by one for Parkinson’s disease targeting GCase – an enzyme linked to Parkinson’s – and another candidate to… May 13, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 28 May 2021 Startup Creator Launched to Fill Europe’s Microbiome Translational Gap …Ysopia Bioscience – are based in Europe. Stellate’s lead asset is a metabolite produced by gut bacteria with neuroprotective qualities. The candidate is on track for clinical trials for Parkinson’s… May 28, 2021 - 6 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 Interview: On the Future of iPS Cells and why Partnering is so Important in this Field …be differentiated into pancreatic beta cells in the case of diabetes, or dopaminergic neurons in the case of Parkinson’s disease, and then be transplanted back into patients to replace their… October 16, 2017 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 21 Aug 2024 The promise of antisense oligonucleotides in precision medicine …α-synuclein and improve symptoms in a mouse model of Parkinson’s disease. Parkinson’s disease has shown a link between the abnormal aggregation of α-synuclein and neuronal death. These aggregates are known… August 21, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 Replay targets genetic brain disorders with new gene therapy company, Kaleibe …formerly CEO at regenerative medicine company, Aspen Neuroscience, Inc. Joe Glorioso, the inventor of synHSV, is also a co-founder of Kaleibe. The initial development programs will focus on genetic Parkinson’s… December 14, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 May 2025 Finland: Pushing biotech forward in the land of a thousand lakes …enabling subcutaneous administration while retaining the neuroprotective properties of CDNF. HER-096 targets the unfolded protein response and brain inflammation triggered by alpha-synuclein aggregation, key factors in the progression of Parkinson’s… May 23, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Sponsored by Collaborative Drug Discovery Inc. 25 Feb 2025 How a virtual company leveraged data to accelerate drug development for neurodegenerative diseases …in-person therapeutic index.” Initial indications for its lead TRPML1 program will likely be ALS and Parkinson’s disease, although Gill believes there is much wider potential. “There may be an opportunity… February 25, 2025 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Sponsored by WuXi AppTec 22 Sep 2021 Discovering New Therapeutic Targets for Alzheimer’s Disease …disease models, and patient-derived cell lines, as well as a variety of sophisticated animal models for Alzheimer’s, Parkinson’s disease, encephalomyelitis, and amyotrophic lateral sclerosis. “As our understanding of genomics and… September 22, 2021 - 7 minutesmins - By Julia Kaiser Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2023 SandboxAQ launches new division to boost drug development …in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and UC San Francisco. Paul Hudson,… June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases …figure is expected to double every 20 years as the population ages. The total direct and informal care costs of Alzheimer’s, Parkinson’s and related disorders are expected to surpass €350… January 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS 3P BioPharmaceuticals and BrainEver are to collaborate on developing hEng1, a recombinant homeoprotein, to treat pathologies such as amyotrophic lateral sclerosis (ALS) or Parkinson’s disease. 3P BioPharmaceuticals is a contract… November 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email